CSPM EDP Sciences logo
Access to submission and peer review system
Search
Menu
All issues Volume 6 (2025) Vis Cancer Med, 6 (2025) 11 References
Open Access
Review
Issue
Vis Cancer Med
Volume 6, 2025
Article Number 11
Number of page(s) 8
DOI https://doi.org/10.1051/vcm/2025009
Published online 04 August 2025
  1. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med 2008;359(11):1143–1154. [Google Scholar]
  2. Argiris A, Karamouzis MV, Raben D, et al. Head and neck cancer. Lancet. 2008;371(9625):1695–1709. [Google Scholar]
  3. Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355(9208):949–955. [Google Scholar]
  4. Tao Y, Rezai K, Brain E, et al. A phase I trial combining oral cisplatin (CP Ethypharm) with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma. Radiother Oncol. 2011;98(1):42–47. [Google Scholar]
  5. Tao Y, Bardet E, Rosine D, et al. Phase I trial of oral etoposide in combination with radiotherapy in head and neck squamous cell carcinoma – GORTEC 2004-02. Radiat Oncol. 2013;8:40. [Google Scholar]
  6. Calais G, Bardet E, Sire C, et al. Radiotherapy with concomitant weekly docetaxel for Stages III/IV oropharynx carcinoma. Results of the 98–02 GORTEC Phase II trial. Int J Radiat Oncol Biol Phys. 2004;58(1):161–166. [Google Scholar]
  7. Borel C, Sun X, Coutte A, et al. 914MO Standard versus fractionated high dose cisplatin concomitant with radiotherapy in locally advanced head & neck squamous cell cancer (LA-HNSCC): Results of the GORTEC 2015–02 CisFRad randomized trial. Ann Oncol 2020;31:S660. [Google Scholar]
  8. Denis F, Garaud P, Bardet E, et al. Final results of the 94–01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 2004;22(1):69–76. [Google Scholar]
  9. Pignon JP, Le Maitre A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17, 346 patients. Radiother Oncol. 2009;92(1):4–14. [Google Scholar]
  10. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006;368(9538):843–854. [Google Scholar]
  11. Bourhis J, Lapeyre M, Tortochaux J, et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. J Clin Oncol. 2006;24(18):2873–2878. [Google Scholar]
  12. Bourhis J, Lapeyre M, Tortochaux J, et al. Accelerated radiotherapy and concomitant high dose chemotherapy in non resectable stage IV locally advanced HNSCC: results of a GORTEC randomized trial. Radiother Oncol. 2011;100(1):56–61. [Google Scholar]
  13. Tao Y, Auperin A, Graff P, et al. Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials. Oral Oncol. 2017;71:61–66. [Google Scholar]
  14. Bourhis J, Sire C, Graff P, et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99–02): an open-label phase 3 randomised trial. Lancet Oncol. 2012;13(2):145–153. [Google Scholar]
  15. Tao Y, Aupérin A, Graff P, et al. Concurrent chemoradiation therapy versus acceleration of radiation therapy with or without concurrent chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): 7-Year Survival Data From a Phase 3 Randomized Trial and Prognostic Factors. Int J Radiat Oncol Biol Phys. 2016;96(2):E324–E325. [Google Scholar]
  16. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357(17):1705–1715. [Google Scholar]
  17. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357(17):1695–1704. [Google Scholar]
  18. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999;91(24):2081–2086. [Google Scholar]
  19. Geoffrois L, Martin L, De Raucourt D, et al. Induction chemotherapy followed by cetuximab radiotherapy is not superior to concurrent chemoradiotherapy for head and neck carcinomas: results of the GORTEC 2007–02 Phase III Randomized Trial, J Clin Oncol. 2018;36(31):3077–3083. [Google Scholar]
  20. Tao Y, Geoffrois L, Martin L, et al. Impact of p16 expression on induction taxotere-cisplatin-5 FU (TPF) followed by cetuximab-radiotherapy in N2b–N3 head and neck squamous cell carcinoma (HNSCC): Results of GORTEC 2007-02 phase III randomized trial. J Clin Oncol. 2017;35(15_suppl):6070. [Google Scholar]
  21. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–578. [Google Scholar]
  22. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–1127. [Google Scholar]
  23. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21–28. [Google Scholar]
  24. Mangoni M, Yue X, Morin C, et al. Differential effect triggered by a heparan mimetic of the RGTA family preventing oral mucositis without tumor protection. Int J Radiat Oncol Biol Phys. 2009;74(4):1242–1250. [Google Scholar]
  25. Tao Y, Auperin A, Sire C, et al. Multicenter randomized double-blind, placebo-controlled trial GORTEC (Groupe Oncologie Radiotherapie Tete et Cou) 2009–01. Evaluating the effect of the regenerating agent on radiodermatitis of head and neck cancer patients. Int J Radiat Oncol Biol Phys. 2017;99(3):590–595. [Google Scholar]
  26. Tao Y, Auperin A, Sire C, et al. Improved outcome by adding concurrent chemotherapy to cetuximab and radiotherapy for locally advanced head and neck carcinomas: results of the GORTEC 2007–01 Phase III Randomized Trial. J Clin Oncol. 2018;JCO2017762518. [Google Scholar]
  27. Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov. 2012;11(2):109–124. [Google Scholar]
  28. The Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536):576–582. [CrossRef] [PubMed] [Google Scholar]
  29. Thibault B, Genre L, Le Naour A, et al. DEBIO 1143, an IAP inhibitor, reverses carboplatin resistance in ovarian cancer cells and triggers apoptotic or necroptotic cell death. Sci Rep. 2018;8(1):17862. [Google Scholar]
  30. Matzinger O, Viertl D, Tsoutsou P, et al. The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNFalpha-mediated in head and neck squamous cell carcinoma. Radiother Oncol. 2015;116(3):495–503. [Google Scholar]
  31. Bourhis J, Sun XS, Tao Y. Letter to the Editor: SMAC mimetics inhibit human T cell proliferation and fail to augment type 1 cytokine responses. Cell Immunol. 2024;395–396:104772. [Google Scholar]
  32. Tao Y, Le Tourneau C, Bouchaab H, et al. PV-0518: Phase 1 study of Debio 1143 in combination with Concurrent Chemo-Radiotherapy in LA-SCCHN. Radiothera. Oncol. 2016;119:S245–S246. [Google Scholar]
  33. Le Tourneau C, Tao Y, Gomez-Roca C, et al. Phase I trial of Debio 1143, an antagonist of inhibitor of apoptosis proteins, combined with cisplatin chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. Clin Cancer Res. 2020;26(24):6429–6436. [Google Scholar]
  34. Sun XS, Tao Y, Le Tourneau C, et al. Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study. Lancet Oncol. 2020;21(9):1173–1187. [CrossRef] [PubMed] [Google Scholar]
  35. Bourhis J, Sun XS, Tao Y. An imbalance in competing mortality favouring Debio 1143 – Authors’ reply. Lancet Oncol. 2020;21(11):e503. [Google Scholar]
  36. Tao Y, Sun XS, Pointreau Y, et al. Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial. Eur J Cancer. 2023;183:24–37. [Google Scholar]
  37. Tao Y, Sun XS, Pointreau Y, et al. Long-term results from a clinical study of xevinapant plus chemoradiotherapy in people with high-risk locally advanced squamous cell carcinoma of the head and neck: a plain language summary. Future Oncol. 2023;19(26):1769–1776. [Google Scholar]
  38. Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956–965. [Google Scholar]
  39. Ferris RL, Blumenschein GJr., J Fayette, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–1867. [Google Scholar]
  40. Cohen EEW, Soulieres D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393(10167):156–167. [Google Scholar]
  41. Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915–1928. [CrossRef] [PubMed] [Google Scholar]
  42. Herrera FG, Bourhis J, Coukos G. Radiotherapy combination opportunities leveraging immunity for the next oncology practice. CA Cancer J Clin. 2017;67(1):65–85. [Google Scholar]
  43. Levy A, Chargari C, Marabelle A, et al. Can immunostimulatory agents enhance the abscopal effect of radiotherapy? Eur J Cancer. 2016;62:36–45. [Google Scholar]
  44. Shaverdian N, Lisberg AE, Bornazyan K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017;18(7):895–903. [Google Scholar]
  45. Bourhis J, Sire C, Tao Y, et al. LBA38 Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 “PembroRad” randomized trial. Ann Oncol. 2020;31:S1168. [Google Scholar]
  46. Tao Y, Biau J, Sun XS, et al. Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015–01 PembroRad): a multicenter, randomized, phase II trial. Ann Oncol. 2023;34(1):101–110. [Google Scholar]
  47. Machiels JP, Tao Y, Licitra L, et al. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2024;25(5):572–587. [Google Scholar]
  48. Machiels JP, Tao Y, Burtness B, et al. LBA5 Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC). Ann Oncol. 2022;33:S1399. [Google Scholar]
  49. Tao Y, Auperin A, Sun XS, et al. Avelumab-cetuximab-radiotherapy (RT) versus standards of care (SoC) in locally advanced squamous cell carcinoma of the head and neck (SCCHN): Safety phase of the randomized trial GORTEC 2017–01 (REACH). J Clin Oncol. 2018;36(15_suppl):6076. [Google Scholar]
  50. Tao Y, Auperin A, Sun X, et al. Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017–01 (REACH). Eur J Cancer. 2020;141:21–29. [Google Scholar]
  51. Bourhis J, Tao Y, Sun X, et al. LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial. Ann Oncol. 2021;32:S1310. [Google Scholar]
  52. Tao Y, Auperin A, Sun X, et al. 854MO Avelumab-cetuximab-radiotherapy (RT) versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Final analysis of randomized phase III GORTEC 2017-01 REACH trial. Ann Oncol. 2024;35:S616. [Google Scholar]
  53. Mirghani H, Even C, Larive A, et al. 653O Neoadjuvant nivolumab (N) before chemoradiation (CRT) in high-risk HPV driven oropharynx cancer (OPC) – IMMUNEBOOST-HPV: A multicenter randomized phase II trial. Ann Oncol. 2022;33:S840–S841. [Google Scholar]
  54. Castelli J, Sun X, Neveu E, et al. 852MO REWRITE–GORTEC 2018-02: Radiotherapy-durvalumab without prophylactic neck irradiation in squamous cell carcinoma of the head and neck. Ann Oncol. 2024;35:S615. [Google Scholar]
  55. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):1945–1952. [Google Scholar]
  56. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350(19):1937–1944. [Google Scholar]
  57. Racadot S, Thennevet I, Ouldbey Y, et al. Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: Results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010–02). Eur J Cancer. 2023;178:114–127. [Google Scholar]
  58. Ferris RL, Spanos WC, Leidner R, et al. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial. J Immunother Cancer. 2021;9(6):e002568. [Google Scholar]
  59. Ferrarotto R, Amit M, Nagarajan P, et al. Pilot Phase II Trial of neoadjuvant immunotherapy in locoregionally advanced, resectable cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res. 2021;27(16):4557–4565. [Google Scholar]
  60. Uppaluri R, Campbell KM, Egloff AM, et al. Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: a multicenter, phase ii trial. Clin Cancer Res. 2020;26(19):5140–5152. [CrossRef] [PubMed] [Google Scholar]
  61. Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973–1985. [Google Scholar]
  62. Wakelee H, Liberman M, Kato T, et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med. 2023;389(6):491–503. [Google Scholar]
  63. Patel SP, Othus M, Chen Y, et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med. 2023;388(9):813–823. [Google Scholar]
  64. Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst. 2009;101(7):498–506. [Google Scholar]
  65. Lefebvre JL, Pointreau Y, Rolland F, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol. 2013;31(7):853–859. [Google Scholar]
  66. Janot F, de Raucourt D, Benhamou E, et al. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol. 2008;26(34):5518–5523. [Google Scholar]
  67. Tao Y, Faivre L, Laprie A, et al. Randomized trial comparing two methods of re-irradiation after salvage surgery in head and neck squamous cell carcinoma: Once daily split-course radiotherapy with concomitant chemotherapy or twice daily radiotherapy with cetuximab. Radiother Oncol. 2018;128(3):467–471. [Google Scholar]
  68. Tortochaux J, Tao Y, Tournay E, et al. Randomized phase III trial (GORTEC 98–03) comparing re-irradiation plus chemotherapy versus methotrexate in patients with recurrent or a second primary head and neck squamous cell carcinoma, treated with a palliative intent. Radiother Oncol. 2011;100(1):70–75. [Google Scholar]
  69. Tao Y, Auperin A, Blanchard P, et al. Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004–01 randomized phase III trial. Radiother Oncol. 2020;150:18–25. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.